Education
About Us
Working with TipRanks
Follow Us
MacroGenics (MGNX)
NASDAQ:MGNX
MGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.89 - $19.54
Previous CloseN/A
Volume157.79K
Average Volume (3M)597.37K
Market Cap
$125.21M
Enterprise Value$39.31M
Total Cash (Recent Filing)$220.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.25
Next Earnings
May 13, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding62,763,447
10 Day Avg. Volume492,025
30 Day Avg. Volume597,371
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.90
Price to Cash Flow (P/CF)0.50
P/FCF Ratio0.50
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.78
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$7.00Price Target Upside250.00% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
MacroGenics News
PremiumCompany Announcements
MacroGenics Inc’s 2024 Earnings Call Highlights
PremiumCompany Announcements
MacroGenics Reports 2024 Financial Results and Progress
PremiumCompany Announcements
MacroGenics Extends CEO’s Separation Agreement
PremiumCompany Announcements
MacroGenics Announces Leadership Transition in Financial Roles
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMGNX ended the quarter with a strong cash position of $200.4M, providing a cash runway into 2026.
Strategic FocusThe sale of global rights to Margenza to TerSera Therapeutics for $40M upfront is viewed positively as it provides non-dilutive financing and allows the company to focus on its pipeline efforts.
Bears Say
Growth ProspectsMacroGenics paused all other vobra duo development efforts in alternative tumor types, impacting growth prospects.
Product Development ChallengesMacroGenics does not plan to move vobra duo forward given the unfavorable safety profile.
---
Ownership Overview
10.33% Insiders
15.85% Mutual Funds
0.05% Other Institutional Investors
62.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $1.89 and its highest was $19.54 in the past 12 months.
What is MacroGenics’s market cap?
MacroGenics’s market cap is $125.21M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Mar 20, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.279 by $0.039.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.73.
How many shares outstanding does MacroGenics have?
MacroGenics has 62,763,447 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.279. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in MGNX
---
MacroGenics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.00 (250.00% Upside)
$7.00 (250.00% Upside)
Blogger Sentiment
Bullish
MGNX Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 28.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.03%
12-Months-Change
Fundamentals
Return on Equity
-49.85%
Trailing 12-Months
Asset Growth
-11.82%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
---
MGNX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
MacroGenics achieved significant clinical and financial milestones in 2024, marked by a substantial increase in revenues and strong progress in clinical trials. However, increased net losses and operating expenses, along with the discontinuation of vobra duo, present challenges. The company remains financially stable with a solid cash position and is poised for future growth.Read More>---
MGNX Stock 12 Month Forecast
Average Price Target
$7.00
▲(250.00% Upside)
Technical Analysis
Best Analysts Covering MGNX
1 Year
1 Year Success Rate
8/28 ratings generated profit
1 Year Average Return
-20.92%
reiterated a buy rating 5 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -20.92% per trade.
---